The human ROX gene: Genomic structure and mutation analysis in human breast tumors

Genomics

Volumn 49, Issue 2, 1998, Pages 275-282

  Nigro, Cristiana Lo ^a,f   Venesio, Tiziana ^c   Reymond, Alexandre ^d   Meroni, Germana ^a   Alberici, Paola ^a   Cainarca, Silvia ^a   Enrico, Fiorenza ^c   Stack, Maria ^e   Ledbetter, David H ^g   Liscia, Daniel S ^c   Ballabio, Andrea ^a   Carrozzo, Romeo ^a,b  

^a TELETHON INSTITUTE OF GENETICS AND MEDICINE TIGEM   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c MOLINETTE HOSPITAL   (Italy)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e CHRISTIE HOSPITAL   (United Kingdom)

^f GALLIERA HOSPITAL   (Italy)

^g Ospedale San Raffaele ^*

Author keywords

[No Author keywords available]

Indexed keywords

HELIX LOOP HELIX PROTEIN; PROTEIN ROX; UNCLASSIFIED DRUG;

ARTICLE; BREAST TUMOR; CHROMOSOME 17P; CLINICAL ARTICLE; EXON; GENE MUTATION; GENE STRUCTURE; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM;

STAPHYLOCOCCUS PHAGE 3A;

EID: 0008577906     PISSN: 08887543     EISSN: None     Source Type: Journal    
DOI: 10.1006/geno.1998.5241     Document Type: Article

References (45)

1. Amati B., Brooks M. W., Levy N., Littlewood T. D., Evan G. I., Land H. Oncogenic activity of the c-Myc protein requires dimerization with Max. Cell. 72:1993;233-245.
2. Amati B., Dalton S., Brooks M. W., Littlewood T. D., Evan G. I., Land H. Transcriptional activation by the human c-Myc oncoprotein in yeast requires interaction with Max. Nature. 359:1992;423-426.
3. Andreassen A., Oyjord T., Hovig E., Holm R., Florenes V. A., Nesland J. M., Myklebost O., Hoie J., Bruland O. S., Borresen A.-L., Fodstad O. p53 abnormalities in different subtypes of human sarcomas. Cancer Res. 53:1993;468-471.
4. Ayer D. E., Kretzner L., Eisenman R. N. Mad: A heterodimeric partner for Max that antagonizes Myc transcriptional activity. Cell. 72:1993;211-222.
5. Ayer D. E., Lawrence Q. A., Eisenman R. N. Mad-max transcriptional repression is mediated by ternary complex formation with mammalian homologs of yeast repressor sin3. Cell. 80:1995;767-776.
6. Biegel J. A., Burk C. D., Barr F. G., Emanuel B. S. Evidence for a 17p tumor related locus distinct from p53 paediatric primitive neuroectodermal tumors. Cancer Res. 52:1992;3391-3395.
7. Blackwood E. M., Eisenman R. N. Max: A helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. Science. 251:1991;1211-1217.
8. Blackwood E. M., Kretzner L., Eisenman R. N. Myc and Max function as a nucleoprotein complex. Curr. Opin. Genet. Dev. 2:1992a;227-235.
9. Blackwood E. M., Luscher B., Eisenman R. N. Myc and Max associate in vivo. Genes Dev. 6:1992b;71-80.
10. Carrozzo R., Ledbetter D. H. Dinucleotide repeat polymorphism mapping to the critical region for lissencephaly (17p13.3). Hum. Mol. Genet. 2:1993;615.
11. Devilee P., Van den Broek M., Kuipers-Dijkshoorn N., Kolluri R., Meera Khan P., Pearson P. L., Cornelisse C. J. At least four different chromosomal regions are involved in loss of heterozygosity in human breast carcinoma. Genomics. 5:1989;554-560.
12. Dib C., Faure S., Fizames C., Samson D., Drouot N., Vignal A., Millasseau P., Marc S., Hazan J., Seboun E., Lathrop M., Gyapay G., Morissette J., Weissenbach J. A comprehensive genetic map of the human genome based on 5,264 microsatellites. Nature. 380:1996;152-154.
13. Eagle L. R., Yin X., Brothman A. R., Williams B. J., Atkin N. B., Prochownik E. V. Mutation of the MXI1 gene in prostate cancer. Nat. Genet. 9:1995;249-255.
14. Edelhoff S., Ayer D. E., Zervos A. S., Steingrimsson E., Jenkins N. A., Copeland N. G., Eisenman R. N., Brent R., Disteche C. M. Mapping of two genes encoding members of a distinct subfamily of MAX interacting proteins: MAD to human chromosome 2 and mouse chromosome 6, and MXI1 to human chromosome 10 and mouse chromosome 19. Oncogene. 9:1994;665-668.
15. Evan G. I., Littlewood T. D. The role of c-myc in cell growth. Curr. Opin. Genet. Dev. 3:1993;44-49.
16. Futreal P., Liu Q., Shattuck-Eidens D., Cochran C., Harshman K., Tavtigian S., Bennett L., Haugen-Strano A., Swensen J., Miki Y., Eddington K., McLure M., Frye C., Weaver-Feldhaus J., Ding W., Gholami Z., Söderkvist P., Terry L., Jhanwar S., Berchuck A., Iglehart J., Marks J. D. G., Barret J., Skolnick M., Kamb A., Wiseman R. BRCA1 mutations in primary breast and ovarian carcinomas. Science. 266:1994;120-122.
17. Graham F. L., Van der Eb A. J. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology. 2:1973;456-464.
18. Hurlin P. J., Foley K. P., Ayer D. E., Eisenman R. N., Hanahan D., Arbeit J. M. Regulation of Myc and Mad during epidermal differention and HPV-associated tumorigenesis. Oncogene. 11:1995a;2487-2501.
19. Hurlin P. J., Quéva C., Eisenmann R. N. Mnt, a novel Max-interacting protein is coexpressed with Myc in proliferating cells and mediates repression at Myc binding sites. Genes Dev. 11:1997;44-58.
20. Hurlin P. J., Queva C., Koskinen P. J., Steingrimsson E., Ayer D. E., Copeland N. G., Jenkins N. A., Eisenman R. N. Mad3 and Mad4: Novel Max-interacting transcriptional repressors that suppress c-myc dependent transformation and are expressed during neural and epidermal differentiation. EMBO J. 14:1995b;5646-5659.
21. Larsson L.-G., Petterson M., Oberg F., Nilsson K., Luscher B. Expression of mad, mxi1, max and c-myc during induced differentiation of hematopoietic cells: Opposite regulation of mad and c-myc. Oncogene. 9:1994;1247-1252.
22. Ledbetter S. A., Kuwano A., Dobyns W. B., Ledbetter D. H. Microdeletions of chromosome 17p13 as a cause of isolated lissencephaly. Am. J. Hum. Genet. 50:1992;182-189.
23. Lo Nigro C., Chong S. S., Smith A. C. M., Dobyns W. B., Carrozzo R., Ledbetter D. H. Point mutations and an intragenic deletion in LIS1, the lissencephaly causative gene in isolated lissencephaly sequence and Miller-Dieker syndrome. Hum. Mol. Genet. 6:1997;157-164.
24. Lundgren R., Mandahl N., Heim S., Limon H., Henrikson H., Mitelman F. Cytogenetic analysis of 57 primary prostatic adenocarcinomas. Genes Chromosomes Cancer. 4:1992;16-24.
25. Mackay J., Steel C. M., Elder P. A., Forrest A. P. M., Evans H. J. Allele loss on short arm of chromosome 17 in breast cancers. Lancet. 8626:1988;1384.
26. Makos M., Nelkin B. D., Chazin V. R., Cavenee W. K., Brodeur G. M., Baylin S. B. DNA hypermethylation is associated with 17p allelic loss in neural tumors. Cancer Res. 53:1993a;2715-2718.
27. Makos M., Nelkin B. D., Lerman M. I., Latif F., Zbar B., Baylin S. B. Distinct hypermethylation patterns occur at altered chromosome loci in human lung and colon cancer. Proc. Natl. Acad. Sci. USA. 89:1992;1929-1933.
28. Makos M., Nelkin B. D., Reiter R. E., Gnarra J. R., Brooks J., Issacs W., Linehan M., Baylin S. B. Regional DNA hypermethylation at D17S5 precedes 17p structural changes in the progression of renal tumors. Cancer Res. 53:1993b;2719-2722.
29. Makos Wales M., Biel M. A., El Deiry W., Nelkin B. D., Issa J.-P., Cavenee W. K., Kuerbitz S. J., Baylin S. B. p53 activates expression of HIC-1, a new candidate tumor suppressor gene on 17p13.3. Nat. Med. 1:1995;570-577.
30. Malkin D. p53 and the Li-Fraumeni syndrome. Cancer Genet. Cytogenet. 66:1993;83-92.
31. Marshall C. J. Tumor suppressor genes. Cell. 64:1991;313-326.
32. McDonald J. D., Daneshvar L., Willert J. R., Matsumura K., Waldman F., Cogen P. H. Physical mapping of chromosome 17p13.3 in the region of a putative tumor suppressor gene important in medulloblastoma. Genomics. 23:1994;229-232.
33. Merlo G. R., Venesio T., Bernardi A., Cropp C. S., Diella F., Cappa A. P. M., Liscia D. S., Callahan R. Evidence for a second tumor suppressor gene on chromosome 17p linked to high S-phase index in primary human breast carcinomas. Cancer Genet. Cytogenet. 76:1994;106-111.
34. Meroni G., Reymond A., Alkalay M., Borsani G., Tanigami A., Tonlorenzi R., Lo Nigro C., Messali S., Zollo M., Ledbetter D. H., Brent R., Ballabio A., Carrozzo R. ROX: A novel bHLHZip protein expressed in quiescent cells that heterodimerizes with Max, binds a non-canonical "E-box" and acts as a transcriptional repressor. EMBO J. 16:1997;2892-2906.
35. Murre C., McCaw P. S., Baltimore D. A new DNA binding and dimerization motif in immunoglobulin enhancer binding, daughterless, myoD, and Myc proteins. Cell. 56:1989;777-784.
36. Phelan C. M., Larsson C., Baird S., Futreal P. A., Ruttledge M. H., Morgan K., Tonin P., Hung H., Korneluk R. G., Pollak M. N., Narod S. A. The human mammary-derived growth inhibitor (MDGI) gene: Genomic structure and mutation analysis in human breast tumors. Genomics. 34:1996;63-68.
37. Pieretti M., Powell D. E., Gallion H. H., Conway P. S., Case E. A., Turker M. S. Hypermethylation at a chromosome 17 "hot spot" is a common event in ovarian cancer. Hum. Pathol. 26:1995;398-401.
38. Prendergast G. C., Lawe D., Ziff E. B. Association of Myn, the murine homolog of Max, with c-Myc stimulates methylation-sensitive DNA binding and Ras cotransformation. Cell. 65:1991;395-407.
39. Sambrook J., Fritsch E. F., Maniatis T. Molecular Cloning: A Laboratory Manual. 1989;Cold Spring Harbor Laboratory Press, Cold Spring Harbor.
40. Schreiber-Agus N., Chin L., Chen K., Torres R., Rao G., Guida P., Skoultchi A. I., DePinho R. A. An amino-terminal domain of Mxi1 mediates anti-Myc oncogenic activity and interacts with a homolog of the yeast transcriptional repressor SIN3. Cell. 80:1995;777-786.
41. Stack M., Jones D., White G., Liscia D. S., Venesio T., Casey G., Crichton D., Varley J., Mitchell E., Heighway J., Santibanez-Koref M. Detailed mapping and loss of heterozygosity analysis suggests a suppressor locus involved in sporadic breast cancer within a distal region of chromosome band 17p13.3. Hum. Mol. Genet. 4:1995;2047-2055.
42. Thompson M., Jensen R., Oberviller P., Page D., Holt J. Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nat. Genet. 9:1995;444-450.
43. Wagner A. J., Le Beau M. M., Diaz M. O., Hay N. Expression, regulation, and chromosomal localization of the Max gene. Proc. Natl. Acad. Sci. USA. 89:1992;3111-3115.
44. Williamson I. P., Elder P. A., Knowles M. A. The spectrum of Tp53 mutations in bladder carcinoma. Genes Chromosomes Cancer. 9:1994;108-118.
45. Zervos A. S., Gyuris J., Brent R. Mxi1, a protein that specifically interacts with Max to bind Myc-Max recognition sites. Cell. 72:1993;223-232.